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Using animal models to overcome
temporal, spatial and combinatorial challenges
in HIV persistence research
Paul W. Denton1,2,3* , Ole S. Søgaard1,2 and Martin Tolstrup1,2

Abstract
Research challenges associated with understanding HIV persistence during antiretroviral therapy can be categorized
as temporal, spatial and combinatorial. Temporal research challenges relate to the timing of events during establishment and maintenance of HIV persistence. Spatial research challenges regard the anatomical locations and cell
subsets that harbor persistent HIV. Combinatorial research challenges pertain to the order of administration, timing of
administration and specific combinations of compounds to be administered during HIV eradication therapy. Overcoming these challenges will improve our understanding of HIV persistence and move the field closer to achieving eradication of persistent HIV. Given that humanized mice and non-human primate HIV models permit rigorous
control of experimental conditions, these models have been used extensively as in vivo research platforms for directly
addressing these research challenges. The aim of this manuscript is to provide a comprehensive review of these
recent translational advances made in animal models of HIV persistence.
Keywords: HIV, Viral persistence, Latency, Humanized mice, Non-human primates, SIV, SHIV
Background
Key to the development of an HIV cure strategy is gaining
a comprehensive understanding of the reservoir of replication-competent virus that persists despite suppressive
antiretroviral therapy (ART) [1–10]. In vivo studies conducted both in humans and in animal models of HIV persistence provide critical insights regarding establishment
of the reservoir, maintenance of HIV persistence and the
efficacy of combination strategies for the eradication of
persistent virus. Because there is inherent difficulty associated with evaluating these particular aspects of HIV
persistence in clinical trials, preclinical studies in animal
models of HIV disease are important guides to clinical
trial designs. Reviewed here are preclinical studies in
humanized mouse and non-human primate (NHP) HIV
models that seek to overcome temporal, spatial or combinatorial research challenges to gain new insights into
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the establishment, maintenance and eradication of HIV
reservoirs (Fig. 1).

Humanized mice and NHP HIV models
Preclinical animal studies permit systematic characterizations of multiple aspects of HIV infection and viral
persistence under defined conditions including demarcated infection parameters, such as time of infection,
and assured compliance with therapeutic regimens. The
vast majority of HIV persistence research in animal models has been performed using either humanized mice or
NHP HIV models. Feline immunodeficiency virus (FIV)
is the only non-primate lentivirus that causes immunodeficiency and FIV infection models have also been
used in HIV persistence research [11, 12]. However, two
critical challenges associated with translating FIV outcomes to the clinic (i.e., the infected cells are not primate
derived and the virus is not human tropic) are overcome
by humanized mouse and NHP HIV models. Consequently, this review is focused on the latter two models of
HIV persistence.
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Fig. 1 Major challenges in HIV persistence research. Categorical depictions of open questions regarding the establishment, maintenance and
eradication of HIV reservoirs. The purpose of “Kick” agents is to reactivate latent virus while “kill” agents enhance the destruction of cells producing
reactivated virus [129]

Under the umbrella terms “NHP” and “humanized
mice” are a myriad of noteworthy model characteristics.
Regarding NHP, three species have been used in HIV
persistence research to date: rhesus macaques (Macaca
mulatta), pig-tailed macaques (M. nemestrina) and
cynomolgus macaques (M. fascicularis) [13–42]. These
macaques were infected with simian immunodeficiency
virus (SIV) or SIV/HIV chimeric viruses (SHIV) (Fig. 2).
While the macaque species and immunodeficiency virus
combinations may differ between studies, these NHP
models all involve infecting animals that are among
humans’ closest living relatives with virus that is phylogenetically linked to the human tropic virus [43]. NHP
in these experiments are outbred with normal anatomy
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and physiology (e.g., immuno-competence); important parallels to the clinical trials that are performed in
humans. For humanized mice, varieties of humanized
mice and their research applications have been exhaustively reviewed previously [44–57]. The current review
focuses solely on humanized mouse models utilized in
HIV persistence research. Common to these models is
the presence of human cells in immunodeficient mice
that are infected by human-tropic virus which can be
targeted by human drugs. When humanized mice are
bioengineered, multiple animals with the same human
genetics are created. Also, multiple human donors can
be used to make cohorts of mice which allow researchers
to recapitulate the diversity found in clinical trials. The
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Fig. 2 Non-human primate species and viruses utilized in HIV persistence research. NHP and SIV/SHIV combinations are indicated with references
wherein the specified combination was used in the study of HIV persistence. a The Macaque species utilized; b the virus strain(s) utilized; and c the
individual studies using the indicated combination
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general aim during the generation of humanized mice is
to produce animals where a functioning human immune
system is present in vivo, nevertheless the human-cell/
human-virus/human-drug interactions will necessarily
occur within the context of mouse anatomy and physiology during the relatively short experimental window
of a mouse’s lifespan. Thus, NHP and humanized mice
have defined characteristics which relate to advantages
and disadvantages for each model. These characteristics
must be considered when determining which experimental applications are suitable for each model. Examples
of experimental applications that are essentially model
specific include: (1) NHP live much longer than humanized mice which means that a persistence study that
involves long-term therapy would best be conducted in
a NHP system. (2) It is possible to bioengineer “personalized humanized mice” that reproduce a specific human’s
immune system in multiple rodents. Experiments that
require such a defined genetic background for the human
immune cells can only be performed in humanized mice.
As humanized mice are individually bioengineered and
not bred, some notes on the various approaches used for
generating mice used in HIV persistence research are
provided here. The production of humanized mice occurs
during four general phases (Fig. 3). Phase A is the choosing of an immunodeficient mouse strain based on their
ability to engraft human cells and tissues [44–57]. Factors

a
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BALB/c Rag2null γCnull

SCID

NOD/SCID γCnull

Thy-liv humanization

c
Implantation under the kidney
capsule of fetal
liver and thymus
SCID-hu thy/liv
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that may dictate this choice include the level of immunodeficiency exhibited [58], propensity for specific tissue
engraftment with human immune cells (e.g., humanization of intestinal tissues [59, 60]) and transgenic expression of human cytokines and growth factors to improve
human chimerization [54]. Phase B is choosing whether
to precondition the animals with gamma radiation or
chemotherapy. Preconditioning becomes particularly
beneficial when there is a human hematopoietic stem
cell (hHSC) transplantation component to Phase C—the
implantation and/or transplantation of human cells/tissues into the immunodeficient mouse. Phase D is allowing the optimal time for proper chimerization. In the case
of hHSC transplantation, there is typically robust human
immune system chimerization in peripheral blood by
8–12 weeks following transplant. Figure 3 highlights key
variables specific to distinct humanized mice used in HIV
persistence research (i.e., SCID-hu thy/liv; TOM; NSGBLT; NSG-hu; DKO-hu; MoM; NRG-hu and Patientderived) [61–84].
Humanized mice and NHP HIV models have been
used extensively as in vivo systems for characterizing
aspects of virus persistence. These studies are discussed
below within the context of three categories: (1) studies
that examined temporal aspects of persistence by maximizing the use of precision experimental timing (e.g.,
virus exposure and ART initiation); (2) studies focused
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Fig. 3 Chimerization strategies for bioengineering humanized mice utilized in HIV persistence research. a Immunodeficient mouse strains used for
humanization in HIV persistence studies. b Lightning symbols indicate that mice received gamma radiation preconditioning. c The humanization
strategy employed is indicated and the type of human cell and/or tissue transplanted is detailed. d Name associated with each type of resultant
humanized mouse is listed with references wherein that type of humanized mouse was used in the study of HIV persistence
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on the spatial aspects of persistence where specific anatomical locations and cell types as viral reservoirs have
been emphasized; and (3) studies that provided preclinical efficacy measures for interventions that could become
components of a combination strategy to cure HIV.

Temporal research challenges
The identification of infected individuals during the first
days of infection requires extraordinary surveillance in
communities of “at risk” individuals [85]. The difficulties
associated with the assembly of a clinical trial cohort of
individuals at the earliest stages of infection, combined
with the fact that the eclipse phase of HIV infection lasts
nearly 2 weeks [86], limit clinical studies evaluating the
very earliest events in the establishment of HIV persistence to extraordinary circumstances (e.g., the case of
the “Mississippi Baby” where ART was initiated in an in
utero infected infant within 30 h of birth [87]). In contrast, animal models are readily amenable to precision
coordination of experimental variables (e.g., timing of
virus exposure, ART initiation and ART interruptions)
in order to overcome temporal challenges in HIV persistence research.
Several research groups have made important observations about the earliest events involved in the establishment of the persistent HIV reservoir [26, 30, 39,
80]. Two of these groups initiated very early ART for
short-term treatment following parenteral infection:
Bourry et al. at 4 h (NHP) and Li et al. at 6 h (humanized mice) [39, 80]. Both groups continued the ART
for 2 weeks, during which plasma viremia was very low
in the NHP and remained undetected in the limited
amount of blood than can be serially harvested from
humanized mice. In the NHP study, the animals were
harvested at the 2 week time point and multiple tissues
(i.e., spleen, peripheral LN, mesenteric LN, ileum and
colon) were evaluated for the presence of viral DNA and
RNA. Both nucleic acid species were detected in the
spleen and mesenteric LN of multiple animals that initiated ART 4 h post infection. The protocol was different
in the humanized mouse study where a 3 week analytical treatment interruption (ATI) was begun following
the initial 2 weeks of ART and then the animals were
treated with a CD8+ T cell-depleting antibody every
third day for ~2 months. During the ATI and CD8+ T
cell-depletion period, some animals exhibited intermittent low level plasma viremia. Post-mortem analyses
revealed the presence of viral DNA by PCR, but not
viral RNA by in situ hybridization in the humanized
mice that initiated ART 6 h post infection. These studies that used the initiation of ART within a few hours of
infection highlight that HIV persistence is established
within the first hours following infection.
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A separate pair of studies examined NHP which initiated extended ART regimens within days of infection. Okoye et al. initiated ART on Day 7 post infection.
Plasma viremia was reduced during the first weeks of
therapy after which plasma viremia remained undetectable for the >200 days the animals were maintained on
therapy [30]. This study used the quantitative viral outgrowth assay (qVOA) to quantitate the number of resting memory CD4+ T cells harboring latent, replication
competent HIV proviruses (considered to be the greatest obstacle in the search for an HIV cure [3, 8–10]). The
qVOA results are reported as infectious units per million
resting memory CD4+ T cells (IUPM). When Okoye et al.
employed this assay in their study, they failed to detect
the presence of replication competent, persistent virus.
This result indicates that early, prolonged ART severely
limits the size of the persistent viral reservoir. However,
the study by Whitney et al. showed that even when initiating ART on day 3 post infection the persistent viral
reservoir does maintain the capacity to lead to rapid
viremia during ATI [26]. The choice to perform an ATI
after 160 days of ART rather than utilize the qVOA as an
outcome measure revealed that animals treated on day
3 did exhibit viremia soon after cessation of ART even
though they had not exhibited plasma viremia at any
point during the study prior to the ATI. Thus, a functional relevant persistent reservoir was established within
3 days of infection, but not eliminated by 160 days of
ART. Together, these studies reiterate that by the time an
individual can be diagnosed as HIV positive, the persistent viral reservoir has already been established.
The qVOA utilized by Okoye et al. is generally considered to be the current best ex vivo assay for characterizing the replication competent, persistent HIV reservoir
[9, 10] and this assay has been used extensively to measure the size of the latent viral reservoir in patients on
long-term ART that exhibit suppressed viremia [88–97].
Yet several lines of evidence suggest that this resource
intensive assay is not sufficiently sensitive and dynamic
to accurately predict ATI outcomes in HIV eradication
clinical trials. The translational nature of this animal
study-based conclusion is confirmed by clinical data.
Chun et al. reported that an individual with a profoundly
low HIV burden experienced viral rebound following
ATI [98]. Similar clinical outcomes were reported for
the “Boston Patients” and the “Mississippi Baby” where
qVOA was unable to detect the replication competent,
persistent HIV reservoir and ATI were accompanied by
delayed viral rebound in all three individuals [99, 100].
There are three critical challenges associated with
qVOA that could explain why this assay has failed to
accurately predict ATI outcomes in animal models and
in patients [9, 101]. First, cell input dictates the qVOA
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sensitivity. This means that lower IUPM values (the goal
in eradication therapy) necessitate more cells for accurate quantification. Cell yields from NHP and humanized mice are small relative to patient-derived samples
which results in lower assay sensitivity in animal studies. Second, the qVOA will detect both integrated and
unintegrated virus in samples where ART has not yet
exceeded 6 months [9]. This time-on-ART restriction
has major implications for both animal studies which
have relatively short ART duration and eradication studies where qVOA cannot reliably generate baseline IUPM
values for ART-naive participants or for patients experiencing viral rebound following an ATI. Third, the stimulatory culture conditions in qVOA are not suitable to
reactivate all latent viral genomes present (i.e., the qVOA
conservatively underestimates the size of the latent viral
reservoir by ~60-fold because of the stochastic nature of
virus reactivation even under maximum stimulatory conditions) [93]. The net effect of this underestimation is a
potentially large, yet undefined gap between the recorded
and actual IUPM values [93] that is coupled to a wide
assay confidence interval (~±0.7 log10 IUPM) [102, 103].
Together, these mean that changes in IUPM from baseline during eradication therapy should be greater than
0.7 log10 before changes can be ascribed to the intervention and not to random virus reactivation events during
the conduct of the assay. Gaining this level of resolution
requires high cell numbers which leads back to the first
challenge mentioned in this paragraph. Thus, while the
qVOA may be a suitable binary marker for reduction in
the size of the latent reservoir to below detection, the
qVOA is unable to serve as a reliable dynamic biomarker
for moderate changes in the size of the latent reservoir
caused by eradication therapy. ATI is a more sensitive
and informative outcome when curative strategies are
being investigated.

Spatial research challenges
The principle anatomical site examined in clinical studies is the peripheral blood because it is relatively easily
accessed for clinical analyses. The intestines and lymph
nodes are the next most frequently examined anatomical location in patients [93, 95, 104–107]. Importantly,
each of these sites has been characterized as important in HIV persistence. Knowing that the anatomical
sites examined so far harbor persistent virus provides
strong rationale for the examination of additional anatomic sites which may also provide refuge for the virus.
Comprehensive characterization of all putative reservoir sites is important because a clear understanding of
the distinct anatomical locations, as well as the specific
cell types within these locations that harbor persistent
virus, is essential to ensure appropriate penetration of
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drugs during eradication therapy. Animal models facilitate analyses that overcome spatial challenges in HIV
persistence research as they make it feasible to simultaneously examine many anatomical compartments, as
well as specific cell subsets at these sites, for the presence
of persistent virus. The efforts of many research groups
working to overcome spatial challenges in HIV persistence research have been stratified into categories by
general topic of investigation and then discussed.
Resting memory CD4+ T cells as persistent virus reservoirs

A limited number of animal research studies have
employed the qVOA to quantitate the latent viral reservoir. These include a pair of NHP studies and a trio of
humanized mouse studies that defined the viral reservoir during ART. In the NHP studies by Shen et al. and
Dinoso et al., either 2- or 3-drug ART was administered
for 5–6 months during which low level plasma viremia
remained detectable in most animals [17, 23]. Replication competent persistent virus was detected in cells
isolated from peripheral blood and lymph nodes at very
low IUPM in both studies. In the three humanized mouse
studies, the qVOA was performed on resting memory
CD4+ T cells that were pooled from multiple organ systems within the same animal [65, 67, 69]. The humanized
mice utilized by Choudhary et al. and Denton et al. harbored a full complement of human hematopoietic cells
while the mice used by Honeycutt et al. were reconstituted solely with human T cells [T-cell only mice (TOM)]
(Fig. 3). In all 5 studies, resting memory CD4+ T cells
harboring replication competent virus were recovered at
IUPM levels analogous to patients on ART. As no animal
study to date has continued ART beyond 6 months, and
some of the NHP data was generated in untreated animals, the published IUPM values in these models include
both stably integrated persistent virus as well as unintegrated virus [9].
Myeloid‑lineage cells as persistent virus reservoirs

While several NHP studies have focused on neurological tissues and the potential role of myeloid-lineage
cells as viral reservoirs, the presence of T cells in the
animals increases the challenges associated with defining the cell lineage(s) harboring persistent virus [13,
22, 27, 28]. To address this, a novel use of humanized
mice has been recently described by Honeycutt et al.
[77]. The mice used in this study are NOD/SCID animals that received a bone marrow transplant of hHSCs
(Fig. 2) such that the animals are systemically reconstituted with human monocytes/macrophages, B cells and
dendritic cells [108]. Notably, these mice lack human T
cells [109]. These mice, referred to as myeloid-only mice
(MoM), exhibit a general lack of detectable viral DNA in
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their peripheral blood cells during HIV infection. This is
reversible by the administration of granulocyte colony
stimulating factor (G-CSF) which leads to blood cell viral
DNA becoming detectable within 6 days of administration. This finding could mean that circulating monocytes
are generally not infected in this model, but mobilization
of the tissue macrophages with G-CSF leads to the presence of infected cells in the blood [77]. MoM have only
been presented in a conference abstract to date. The publication of comprehensive data from this model is likely
to increase our understanding of the role played by the
myeloid lineages in HIV persistence.
Hematopoietic stem cells, splenocytes and thymocytes
as persistent virus reservoirs

Hematopoietic stem cells are long-lived, self-renewing
cells that have the potential to perpetuate integrated HIV
DNA for a very long time. Carter et al. showed that hHSC
infected with CXCR4-tropic HIV and then transplanted
into immunodeficient mice are capable of multi-lineage
engraftment of these animals [79]. Subsequently, Nixon
et al. showed that CXCR4-tropic HIV can infect hHSC
in vivo in humanized mice [78]. However, the bulk of
HIV variants do not use CXCR4 as a co-receptor for viral
entry which should limit the contribution of HSC in virus
persistence. This conclusion is consistent with the observation that HIV DNA was not detected in highly purified
CD34+ HSC from patients on long-term ART [110].
In addition to hHSC, the Zack Laboratory has also
examined the role of splenocytes [71] and thymocytes
[61–64, 70, 72] in HIV persistence in humanized mice.
Viral persistence in splenocytes infected with a murine
heat-stable antigen (HSA)-reporter virus was studied
by Marsden et al. in the absence of ART because this
reporter system allowed them to evaluate viral persistence in the context of ongoing virus replication in the
untreated animals [71]. To identify persistently infected
cells ex vivo, HSA+ splenocytes were immuno-depleted.
The HSAneg splenocytes were then stimulated in culture
in the presence of raltegravir to inhibit virus spread and
to limit unintegrated viral DNA from confounding the
data interpretation. Culture supernatants were examined
for Gagp24 by ELISA and it was determined that splenocytes did harbor latent HIV in vivo but the specific cell
lineage(s) that harbored persistent virus were not elucidated in this study. Years earlier, this same reporter virus
was used by Brooks et al. to demonstrate that thymocytes
also could harbor persistent HIV [61]. The mice used
in the earlier study were engrafted with a human thymus, but did not exhibit systemic human engraftment,
such that the only anatomical compartment examined
in this report was the thymus. A subsequent study on
HIV persistence in thymocytes showed that harboring
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a transcriptionally silent HIV provirus did not alter cell
surface phenotypes during differentiation and maturation of T cells [62]. In contrast to the humanized mouse
studies, however, Shen et al. reported that thymocytes
were not the source of persistent virus in a NHP model
when the animals were undergoing ART [23].
Together, these studies indicate that hematopoietic
stem cells, splenocytes and thymocytes all have the
potential to serve as cellular reservoirs of persistent virus,
although these cell types likely do not harbor the bulk of
virus that persists during long-term ART in patients. In
addition, the replication competence of persistent virus
in these cell lineages remains an open question.
Anatomical location of persistent virus

Multiple research groups have sought to characterize
the anatomical distribution of persistent virus during
ART in NHP models. Three groups performed extensive
survey studies and reported on the levels of persistent
virus present in tissues throughout the body [20, 21, 29,
35]. In these papers, viral DNA and RNA quantitations
from lymphoid, gastrointestinal, neurological and reproductive tissues as well as other tissues from the urinary,
respiratory and circulatory tracts showed that the bulk
of persistent viral nucleic acids were present in lymphoid
and gastrointestinal tissues during ART. In a more tissue
specific study, Matusali et al. found that virus persisted
at higher levels throughout the male genital tract and in
the semen of adult cynomolgus macaques on ART than
was observed by North et al. in juvenile rhesus macaques
[21, 33]. Matusali et al. also found that virus shedding in
semen during ART was reduced in some animals following ART intensification with raltegravir. Viral persistence
in the central nervous system of NHP was the focus of
a series of manuscripts from the Clements Laboratory
[13, 22, 27, 28]. Beyond the importance of identifying
persistent virus in this anatomical location, a key finding
in these works was the observation that virus coding for
cytotoxic T lymphocytes (CTL) escape mutations were
archived in the central nervous system during ART [22].
Surprisingly, given the intense focus on the intestines as
a major anatomical site harboring persistent virus [20,
21, 29, 35, 111–124], there is no published evidence from
humans or animal models that replication competent,
latent HIV proviruses persist in the intestines during
ART.
Common to these anatomical location analyses were
their reliance upon nucleic acid measures of viral persistence. The HIV DNA measures do not distinguish
between defective archived virus and replication competent virus. Thus, these nucleic acid measures overestimate the amount of replication competent virus that
must be targeted by any successful HIV eradication
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strategy [9]. The presence of HIV RNA indicates that
expression has occurred recently, but neither nucleic acid
determination can measure the level of replication competent, transcriptionally silent proviruses [88].
Lymphoid tissues, particularly lymph nodes, were
the focus of several other virus persistence studies [17,
18, 23]. These studies reiterated the importance of lymphoid tissues as anatomical locations that harbor persistent virus during ART. Fukazawa et al. examined the
architecture of lymph nodes as a means to gain mechanistic insights into the reason that viruses persist in these
organs [18]. They noted that virus producing CD4+ T follicular helper cells in the B cell follicles were not susceptible to immune clearance. They identified B cell follicles as
regions of the lymph nodes that experience very limited
infiltration by CTL. CTL exclusion from B cell follicles
was described in elite controller NHP although this phenotype would also be expected during ART. In addition
to nucleic acid measures of viral persistence, this study
included the use the qVOA to demonstrate that the persistent viral reservoirs in the lymph nodes include replication competent virus.
Novel strategy for the non‑invasive detection of persistent
HIV in vivo

Santangelo et al. recently described a novel immunoPET
scan technique that they were able to use for non-invasive identification of the anatomical locations with ongoing virus production during ART in NHP [41]. This study
showed that cells in lymphoid tissues and the intestines
continue to exhibit virus protein expression during ART
which is in keeping with other studies in animal models and patient biopsy data. The key contribution of this
study is its description of a technique for the detection
of virus production in multiple anatomical sites simultaneously that has the potential to be refined and applied
broadly in HIV cure research.

Combinatorial research challenges
The success of ART hinges on the combination of multiple antiretroviral agents [125]. It has been suggested
that an effective HIV eradication therapy will also combine multiple interventions [126–128]. Potential classes
of interventions that may be included in an eradication
cocktail are: HIV reactivating compounds, immune modulatory compounds and virus suppressive compounds
[1–8]. Specific drug combinations as well as the order,
timing and frequency of drug administration can all be
validated preclinically in animal models prior to designing clinical studies. Such an approach will improve the
rational design of clinical studies to increase their probability of successfully achieving trial endpoints. Most
animal studies have evaluated the impact of ART plus a
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single intervention on virus persistence with the expectation that combinations will be evaluated in NHP or
humanized mice subsequently. These studies are discussed in the following paragraphs according to topic.
Strategies to reactivate latent virus

The concept of viral reactivation in the context of a “kick
and kill” eradication strategy is being pursued aggressively in clinical trials [129] and most agents in testing
for HIV therapy are being developed for or are already
in clinical use for oncology interventions [104, 130–133].
Animal models are ideal in vivo experimental platforms
for the efficacy evaluation of not-yet-approved pharmaceuticals for their capacity to reactivate latent viruses. In
a series of papers from the Zack laboratory, humanized
mice were used to generate latently infected cells which
were subjected to a range of stimulatory agents ex vivo
(e.g., prostratin, PMA, PHA, and cytokines) to identify
T cell signaling pathways involved in latency reversal
[63, 64, 70, 72]. In a separate ex vivo study, Shen et al.
determined that reactivation conditions for SIV in NHP
cells (from animals described in Ref. [23]) did not overlap fully with conditions used for reactivating HIV from
human cells in the context of the qVOA [24]. This outcome indicates that caution should be exercised when
translating latency reactivation in vivo in NHP to clinical expectations; however, similarities between NHP and
human reactivation data have been recently reported.
Specifically, vorinostat given to patients [104, 130, 133]
and NHP [37, 38] during ART caused modest increases
in cell-associated viral RNA. The similar results in both
in vivo systems are encouraging, but the characterization of latency reversal efficacy in NHP and patients during more potent latency reversal therapy will provide
stronger confirmation of the translational nature of the
NHP to clinical outcomes in such studies.
A robust example of the utility of animal models in
overcoming combinatorial research challenges is the
work of Halper-Stromberg et al. in humanized mice.
This group combined multiple strategies to reactivate
latent virus with strategies to improve antiviral immunity and killing of infected cells [74]. A key experiment in
their study was to serially dose (five times) HIV-infected
humanized mice with a mix of three broadly neutralizing antibodies (i.e., 3BNC117, 10-1074 and PG16) which
suppressed plasma viremia. Then the animals received
three separate doses of a combination of three virus reactivating agents. The three virus inducers used in the combination were vorinostat, an HDAC inhibitor; I-BET151,
a BET protein inhibitor; and anti-CTLA-4 antibody, a T
cell inhibitory pathway blocker. The remarkable observation made during this experiment was: even in the
absence of ART, the combinatorial eradication strategy
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employed prevented viral rebound in 57 % of animals.
Even though the dosing and timing of dosing were not
yet optimized in this study, these observations strongly
suggest that combinations of viral inducers appear to be
synergistic in vivo.
Strategies to improve antiviral immunity and the killing
of infected cells

Active immunization, as well as passive immunization,
are strategies being investigated for improving antiviral immunity during virus eradication therapy. Hansen
et al. performed an active immunization of NHP using a
cytomegalovirus (CMV) vector expressing SIV proteins
[19]. This study generated excitement because long-term
control of viremia was observed in the vaccine arm of
the study. Amazingly, a cohort of eight vaccinated animals ceased to exhibit any plasma viremia by ~70 days
post immunization and remained viremia free until necropsy (>160 days post immunization). This effect has
been attributed to atypical CD8+ T cell targeting by the
CMV vector [42]. At harvest the qVOA was utilized to
demonstrate that no replication competent virus could
be recovered from multiple tissues in the immunized animals. This outcome is very encouraging and the hurdles
to implementing this strategy in clinical trials are being
addressed.
Passive immunization with broadly neutralizing antibodies has been evaluated for its therapeutic potential in
humanized mouse and NHP HIV models. The antibodies were administered either in combination with [75]
or in the absence of [16, 73, 76] ART. In all cases, significant reductions in viremia were associated with antibody administration. Furthermore, broadly neutralizing
antibodies combined with ART also led to a reduction
in cell-associated viral DNA. Immunotoxins are a form
of passive immunization where Fab fragments of antibodies are fused with a toxin to deliver the deadly payload to virus expressing cells [134]. Brooks et al. showed
that an immunotoxin that specifically targets HIV envelope-expressing cells kills virus expressing cells following latency reversal ex vivo [63]. Subsequently, Denton
et al. used this immunotoxin to reduce viral persistence
in vivo. The immunotoxin was administered to humanized mice over a 2 week period in conjunction with continued ART [68]. The outcome of this relatively short
immunotoxin therapy in vivo was an additional 1 log10
reduction in tissue viral RNA levels beyond the impact of
ART alone.
In addition to immunization, immunomodulatory
strategies also have the potential to boost antiviral immunity against cells where latent virus has recently been
reactivated. When toll-like receptors (TLR) recognize
distinct foreign molecular patterns, they activate innate
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and adaptive immune cells. Whitney et al. recently published a conference report describing the effect of a TLR7
agonist given to ART-suppressed NHP [31]. In their
study, they observed both reduced viral DNA in blood
and tissues and a marked induction of plasma viremia
following multiple oral administrations of the inhibitor. Furthermore, the viral set point in these animals was
lower during ATI versus animals that did not receive
the TLR7 agonist. The surprising outcome of this study
suggests that it may be possible for a single molecule to
function as both the “kick” and the “kill” component of a
virus eradication strategy. At the least, such a TLR agonist could augment the reactivation of latent virus while
simultaneously functioning as an immune enhancer.
Recently, Deng et al. showed that it is not sufficient to
simply boost antiviral immunity, especially in patients
who initiated ART during chronic infection [66]. The
experimental conditions were highly controlled in this
study as three key experimental components were independently derived from a single human donor who
initiated ART during chronic infection. The three components were: (1) virus grown out from the latent reservoir using the qVOA; (2) ex vivo stimulated CD8+ T cells;
and (3) humanized mice generated from bone marrowderived HSC. The humanized mice were infected with
virus from the patient’s latent viral reservoir and then
received an adoptive transfer of the ex vivo stimulated
CD8+ T cells. The key variable was the reagent used for
the ex vivo CD8+ T cell stimulation. When the stimulation included immune-dominant gag-epitopes based
upon the patient’s HLA genotype, the adoptively transferred cells were unable to control viremia in the recipient humanized mice. However, when the stimulation did
not include epitopes for which escape mutations were
pre-existing, the adoptively transferred cells were capable
of controlling viremia in the recipient humanized mice.
This study yielded two very valuable contributions. First,
when ART is initiated during chronic infection, the latent
virus reservoir harbors CTL escape variants. Second,
vaccination strategies in patients may need to be tailored
for individual HLA genotypes to avoid stimulating ineffective antiviral immunity.
Strategies to suppress virus activity

Different strategies to suppress residual virus replication during ART have been tested in animal models.
North et al. evaluated ART intensification regimens in
NHP [32]. Animals received either 3-, 4-, or 5-drug ART
regimens, but no major differences in viral decay kinetics
were observed and all animals experienced viral rebound
during ATI. Using a complicated delivery strategy, Shytaj et al. combined ART intensification in NHP with
auranofin and buthionine sulfoximine [14, 15, 25]. The
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net effect of this regimen was a substantial alteration in
the natural course of infection that appeared to limit disease progression to AIDS, but did not limit viral rebound
during ATI. Dunham et al. coupled an indoleamine
2,3-dioxygenase inhibitor with ART in NHP, but did not
observe any alteration of the inflammatory environment
in vivo, as hypothesized, nor did they observe an impact
on persistent infection [36]. Moniuszko et al. performed
a similar study with glucocorticoid to reduce the number of proinflammatory CD16+ monocytes present in
NHP on ART [40]. This regimen did reduce the target
cell population, but did not alter the persistent viral DNA
levels relative to ART alone. Mavigner et al. performed
HSC transplants in NHP during ART using autologous
cells to determine the impact of myeloablative total body
irradiation plus stem cell transplant on viral persistence
[34]. One to two months following the transplant, ART
was discontinued in the experimental and control arms
of the study. Rapid viral rebound and similar tissue viral
nucleic levels characterized in the animals from both
groups at necropsy indicated that neither the act of conditioning for a stem cell transplant nor the transplant
itself were sufficient to significantly impact viral persistence. Holt et al., Neff et al., Kitchen et al. and Shimizu
et al. employed various gene editing strategies to successfully reduce viral burden by reducing the number of
human T cells susceptible to viral entry in HIV infected
humanized mice in the absence of ART [81–84]. While
these pioneering studies did not achieve the ultimate
therapeutic goal of virus eradication, they confirm the
feasibility of performing preclinical combinatorial trials
in animal models. Regarding future animal model studies
in HIV persistence, it is noteworthy that high costs and
animal availability are major concerns for researchers
conducting HIV persistence studies in animal models—
particularly for investigators utilizing NHP. The creation
of a core facility that supplies ART-suppressed animals
to HIV persistence researchers could address these concerns, accelerate the work and lower the costs associated
with these lines of research.

Conclusions
Given that experimental conditions are more readily
controlled in animal studies, humanized mice and NHP
are ideal experimental platforms for overcoming temporal, spatial and combinatorial challenges in HIV persistence research. Importantly, since certain studies such
as patient-specific humanized mice and long-term ART
administration in NHP [26, 66] can only be performed in
the respective model utilized, these in vivo HIV models
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have complementing advantages for HIV persistence
researchers. Beyond model specific contributions to
the field of HIV persistence research, both humanized
mice and NHP models have been used independently
to generate correlative data sets regarding viral persistence in anatomical regions outside the typically assayed
primary and secondary lymphoid tissues. Both types of
models have been used to show that the persistent viral
reservoir is established within the very first hours and
days of infection and early ART is insufficient to eradicate the persistent virus. Both types of models have also
been used to perform preclinical efficacy evaluations of
novel combinations of eradication interventions which
will likely be required to achieve a cure for this disease.
Both humanized mice and NHP HIV models should be
utilized to evaluate potential biomarkers of viral rebound
following ATI (e.g., PD-1, TIM-3, and LAG-3 [135]) as
the validation of such markers will simplify clinical cure
trial designs. The generation of these and other translational data in animal HIV models will continue to move
the field closer to a cure for HIV disease.
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